Citations

Showing 10 of 108094 citations.

Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma
Ensign, Shannon P. Fortin , Jenkins, Robert B. , Giannini, Caterina , Sarkaria, Jann N. , Galanis, Evanthia , Kizilbash, Sani H. , Fortin Ensign, Shannon P, Ensign, Shannon P. Fortin , Galanis, Evanthia , Giannini, Caterina , Sarkaria, Jann N , Kizilbash, Sani H

Mayo Clinic

Neuro-Oncology | August 17, 2022 | Volume: 25 | Issue: 1 | Pages: 28-36

10.1093/neuonc/noac205 | PMID 35973817 Get It

Abstract Isocitrate dehydrogenase (IDH) 1 or 2 mutations confer a favorable prognosis compared to IDH-wildtype in astrocytoma, frequently denoting a lower grade malignancy. However, recent molecular profiling has identified specific aggressive tumor subgroups with clear clinical prognostic implications that are independent of histologic grading. The homozygous deletion of CDKN2A/B is the strongest implicated independent indicator of the poor prognosis within IDH-mutant astrocytoma, and the identification of this alteration in these lower histologic grade tumors transforms their biology toward an aggressive grade 4 phenotype clinically. CDKN2A/B homozygous deletion is now sufficient to define a grade 4 tumor in IDH-mutant astrocytomas regardless of histologic appearance, yet there are currently no effective molecularly informed targeted therapies for these tumors. The biological impact of CDKN2A/B homozygous deletion in IDH-mutant tumors and the optimal treatment strategy for this molecular subgroup remains insufficiently explored. Here we review the current understanding of the translational significance of homozygous deletion of CDKN2A/B gene expression in IDH-mutant astrocytoma and associated diagnostic and therapeutic implications.
Psychiatric diagnostic dilemmas among people with intellectual and developmental disabilities
Charlot, Lauren , Hodge, Steven M. , Holland, Ashley , Frazier, Jean A. , Charlot, L R , Hodge, S M , Holland, A L , Frazier, J A

Mayo Clinic

Journal of Intellectual Disability Research | August 17, 2022 | Volume: 66 | Issue: 10 | Pages: 805-816

10.1111/jir.12972 | PMID 35974452 Get It

Abstract Background Research regarding the accuracy of co‐morbid psychiatric diagnoses in individuals with intellectual and developmental disabilities (IDD) is sparse. Yet correct diagnostic assignment is vital so that effective and appropriate treatment can be implemented, especially for the large numbers of individuals requiring expensive and restrictive behavioural health crisis services. Method A retrospective review of de‐identified data from multidisciplinary specialty team assessments completed for 50 individuals with ID (IntellectualDisability) with and without ASD and unresolved behavioural health challenges was conducted. The accuracy and reliability of the psychiatric diagnoses upon referral were compared with the diagnoses after the comprehensive team evaluation, and within‐individual diagnostic agreement was calculated. The agreement between the Mood and Anxiety Semi‐Structured interview tool (MASS) and the full team evaluation was also calculated. The influence of demographic and clinical characteristics on diagnostic agreement was explored. Results The most common chief complaints upon referral were aggression to others and self‐injurious behaviour. Individuals were taking a median of six medications (interquartile range: 5 to 7); 80% were taking an antipsychotic medication. The most common medical conditions were constipation (70%) and gastroesophageal reflux disease (52%). Measures of interrater reliability of the referral diagnoses with the team assessment were below 0.5 (kappa range: −0.04 to 0.39), with the exception of ruling out dementia (kappa = 0.85). The interrater reliability estimates for the MASS evaluations for depression and anxiety were higher (kappa = 0.69 and 0.64) and reflected higher sensitivity and PPV. The odds of any referral diagnosis being confirmed by team evaluation were low: 0.25 (range: 0 to 0.67). The level of diagnostic agreement for each patient was not significantly attributable to demographic or clinical characteristics, although effect sizes indicate a possible positive relationship to age and the number of prescribed psychotropic medications at referral. Conclusion Individuals in the current study had serious psychiatric and behavioural problems despite psychiatric care in their communities. The majority of psychiatric diagnoses provided upon referral were not supported by the multidisciplinary specialty team's assessment. In addition to possible diagnostic inaccuracy, the group in the study suffered from multiple medical co‐morbidities and were exposed to polypharmacy. Results emphasise the importance of multidisciplinary evaluation by clinicians with expertise in neurodevelopmental disabilities when people with ID with and without ASD have complex behavioural health needs that are unresponsive to usual care. In addition, based on agreement with the full team evaluation, the MASS shows promise as an assessment tool, especially with regards to identifying anxiety and depression.
Strategies for Expanding Donors Pool in Heart Transplantation
Jacob, Samuel , Garg, Pankaj , Wadiwala, Ishaq , Yazji, John H , Alomari, Mohammad., Alamouti-fard, Emad, Hussain, Md Walid Akram , Akram Hussain, Md Walid, Pham, Si M. , Wadiwala, Ishaq J , Garg, Pankaj , Alomari, Mohammad

Mayo Clinic

Reviews in Cardiovascular Medicine | August 16, 2022 | Volume: 23 | Issue: 8 | Pages: No page available

10.31083/j.rcm2308285 | PMID 39076623 Get It

Heart transplant remains the criterion standard treatment for patients in end-stage heart failure. Improvement in the post-heart transplant outcomes in the last decade has contributed to increased demand for organs. Worldwide each year, more than 5000 heart transplants are performed and 50,000 people become candidates for heart transplant. In the last 50 years, there have been several attempts to expand donor criteria to increase the donor pool. Despite making hepatitis C virus, opioid overdose death, old age allowable and changing the allocation system, the gap between supply and demand is widening and unfortunately, thousands die every year waiting due to the critical shortage of organs. New technologies for heart donation after circulatory death have emerged, particularly normothermic regional organ perfusion and ex-vivo heart perfusion using organ care systems. However, these technologies still do not fill the gap. Continuous advancements in areas such as regenerative medicine and xenotransplantation, among others, are needed to overcome the shortage of heart donors for heart transplantation.
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
Salles, Gilles , Schuster, Stephen J. , Dreyling, Martin , Fischer, Luca , Patten, Piers , Smith, Sonali M. , Ubieto, Ana Jiménez , Davis, Keith L. , Anjos, Caroline Oliveira dos , Chu, Jufen, Zhang, Jie , Bodoni, Chiara Lobetti, Thiéblemont, Catherine , Fowler, Nathan , Martínez‐López, Joaquín , Link, Brian K. , Martinez-Lopez, Joaquin , Patten, Piers E M , Smith, Sonali M , Dickinson, Michael , Wang, Yucai , Link, Brian K , Martinez-Lopez, Joaquin , Salles, Gilles A , Dreyling, Martin , Martinez-Lopez, Joaquin , Schuster, Stephen J , Kuruvilla, John , Tresckow, Bastian von , Dickinson, Michael , Wang, Yucai

Mayo Clinic

Blood Advances | August 16, 2022 | Volume: 6 | Issue: 22 | Pages: 5835-5843

10.1182/bloodadvances.2022008150 | PMID 35973192 Get It

Abstract The ELARA trial indicates tisagenlecleucel (tisa-cel) is an effective anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory follicular lymphoma (r/r FL). As ELARA is a single-arm trial, this study compares tisa-cel outcomes from the ELARA trial with usual care from a real-world cohort. ELARA enrolled 98 patients as of 29 March 2021 (median follow-up: 15 months from enrollment). Usual care data were obtained from ReCORD-FL, a global retrospective study of patients with r/r FL, who met similar eligibility criteria to ELARA. With a data cutoff date of 31 December 2020, 187 patients with ≥2 preceding treatment lines were included in the ReCORD-FL (median follow-up: 57 months from third-line) study. An indirect treatment comparison was performed for 97 patients from the ELARA trial and 143 patients from the ReCORD-FL study with no missing data on baseline factors. The line of therapy for which outcomes were assessed was selected or matched between cohorts using propensity score modeling. After baseline factor adjustment via weighting by odds, complete response rate (CRR; 95% confidence interval) was 69.1% (59.8%-78.3%) for tisa-cel vs. 37.3% (26.4%-48.3%) for usual care; overall response rate was 85.6% (78.7%-92.5%) vs. 63.6% (52.5%-74.7%). Kaplan-Meier probability of being progression/event-free at 12 months was 70.5% (61.4%-79.7%) for tisa-cel vs. 51.9% (40.6%-63.3%) for usual care, with hazard ratio (HR)=0.60 (0.34-0.86); 12-month overall survival was 96.6% (92.9%-100%) vs. 71.7% (61.2%-82.2%), with HR=0.2 (0.02-0.38). In conclusion, tisa-cel was associated with a 1.9-fold higher complete response rate and a 1.4-fold higher rate of being progression or event free at 12 months vs usual care, as well as a death risk reduction of 80%. The findings provide additional evidence on the benefit of tisa-cel in patients with r/r FL after ≥2 treatment lines. This trial was registered at www.clinicaltrials.gov as NCT03568461
Histologic Variants of Kaposi Sarcoma in the Gastrointestinal Tract
Zheng, Wei , Obeng, Rebecca C. , Lui, Shu, Cheng, Jerome , Alexiev, Borislav A. , Escobar, David , Liu, Xiuli , Navale, Pooja , Westerhoff, Maria , Xue, Yue , Graham, Rondell P. , Lui, Shu, Quigley, Brian M. , Krasinskas, Alyssa M. , Yang, Guangyu , Reid, Michelle D.

Mayo Clinic

American Journal of Surgical Pathology | August 16, 2022 | Volume: 46 | Issue: 11 | Pages: 1500-1506

10.1097/pas.0000000000001937 | PMID 35973011 Get It

Kaposi sarcoma (KS) can pose diagnostic challenges in biopsy specimens. Multiple histologic variants of cutaneous KS have been described; however, the histomorphologic spectrum of gastrointestinal (GI) KS has not been systematically studied. This large series comprehensively evaluated 46 cases of KS involving the GI tract and identified 7 histomorphologic variants, some that have not been previously described. Five of them are inconspicuous but have unique morphologic patterns, including lymphangioma/lymphangiectatic–like (n=17), mucosal hemorrhage/telangiectatic–like (n=17), mucosal inflammation–like (n=15), granulation tissue–like (n=13), and mucosal prolapse–like (n=4) variants. These variants can be easily misdiagnosed or misinterpreted on routine examination if KS is not considered, and if the immunohistochemical stain for human herpesvirus-8 is not performed. The other 2 morphologic variants present as spindle cell proliferations and are the GI stromal tumor–like (n=8) and inflammatory myofibroblastic tumor–like (n=2). These variants raise a broad differential diagnosis of spindle cell tumors of the GI tract and could pose diagnostic challenges. In summary, GI KS lesions exhibit variable, often unconventional histomorphologic patterns. KS should be included in the differential diagnosis even if features of conventional KS are not seen, particularly in limited biopsies in immunocompromised patients, such as those with human immunodeficiency virus infection. Although the clinical significance of these morphologic variants is yet to be determined, they are nonetheless important from a diagnostic standpoint. Misdiagnosis and delay in appropriate management can be avoided by recognizing the morphologic diversity of GI KS and appropriately utilizing the human herpesvirus-8 immunohistochemical stain.
Risk factors for secondary meniscus tears can be accurately predicted through machine learning, creating a resource for patient education and intervention
Jurgensmeier, Kevin , Till, Sara E., Arguello, Alexandra M. , Saris, Daniël B.F. , Krych, Aaron J. , Krych, Aaron J , Jurgensmeier, Kevin , Lu, Yining , Stuart, Michael J. , Camp, Christopher L.

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | August 16, 2022 | Volume: 31 | Issue: 2 | Pages: 518-529

10.1007/s00167-022-07117-w | PMID 35974194 Get It

AbstractPurposeThis study sought to develop and internally validate a machine learning model to identify risk factors and quantify overall risk of secondary meniscus injury in a longitudinal cohort after primary ACL reconstruction (ACLR).MethodsPatients with new ACL injury between 1990 and 2016 with minimum 2‐year follow‐up were identified. Records were extensively reviewed to extract demographic, treatment, and diagnosis of new meniscus injury following ACLR. Four candidate machine learning algorithms were evaluated to predict secondary meniscus tears. Performance was assessed through discrimination using area under the receiver operating characteristics curve (AUROC), calibration, and decision curve analysis; interpretability was enhanced utilizing global variable importance plots and partial dependence curves.ResultsA total of 1187 patients underwent ACLR; 139 (11.7%) experienced a secondary meniscus tear at a mean time of 65 months post‐op. The best performing model for predicting secondary meniscus tear was the random forest (AUROC = 0.790, 95% CI: 0.785–0.795; calibration intercept = 0.006, 95% CI: 0.005–0.007, calibration slope = 0.961 95% CI: 0.956–0.965, Brier’s score = 0.10 95% CI: 0.09–0.12), and all four machine learning algorithms outperformed traditional logistic regression. The following risk factors were identified: shorter time to return to sport (RTS), lower VAS at injury, increased time from injury to surgery, older age at injury, and proximal ACL tear.ConclusionMachine learning models outperformed traditional prediction models and identified multiple risk factors for secondary meniscus tears after ACLR. Following careful external validation, these models can be deployed to provide real‐time quantifiable risk for counseling and timely intervention to help guide patient expectations and possibly improve clinical outcomes.Level of evidenceIII.
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017
Javle, Milind , Azad, Nilofer S. , Kelley, Robin Kate , Sivaraman, Smitha , Teschemaker, Anna, Chopra, Ishveen , Janjan, Nora A., Parasuraman, Shreekant , Bekaii‐Saab, Tanios , Bekaii-Saab, Tanios S , Lee, Sunyoung , Borad, Mitesh J.

Mayo Clinic

The Oncologist | August 16, 2022 | Volume: 27 | Issue: 10 | Pages: 874-883

10.1093/oncolo/oyac150 | PMID 35972334 Get It

Abstract Background Previous studies report increasing cholangiocarcinoma (CCA) incidence up to 2015. This contemporary retrospective analysis of CCA incidence and mortality in the US from 2001-2017 assessed whether CCA incidence continued to increase beyond 2015. Patients and Methods Patients (≥18 years) with CCA were identified in the National Cancer Institute Surveillance, Epidemiology, and End Results 18 cancer registry (International Classification of Disease for Oncology [ICD-O]-3 codes: intrahepatic [iCCA], C221; extrahepatic [eCCA], C240, C241, C249). Cancer of unknown primary (CUP) cases were identified (ICD-O-3: C809; 8140/2, 8140/3, 8141/3, 8143/3, 8147/3) because of potential misclassification as iCCA. Results Forty-thousand-and-thirty CCA cases (iCCA, n=13,174; eCCA, n=26,821; iCCA and eCCA, n=35) and 32,980 CUP cases were analyzed. From 2001-2017, CCA, iCCA, and eCCA incidence (per 100 000 person-years) increased 43.8% (3.08 to 4.43), 148.8% (0.80 to 1.99), and 7.5% (2.28 to 2.45), respectively. In contrast, CUP incidence decreased 54.4% (4.65 to 2.12). CCA incidence increased with age, with greatest increase among younger patients (18-44 years, 81.0%). Median overall survival from diagnosis was 8, 6, 9, and 2 months for CCA, iCCA, eCCA, and CUP. From 2001-2016, annual mortality rate declined for iCCA (57.1% to 41.2%) and generally remained stable for eCCA (40.9% to 37.0%) and for CUP (64.3% to 68.6%). Conclusions CCA incidence continued to increase from 2001-2017, with greater increase in iCCA versus eCCA, whereas CUP incidence decreased. The divergent CUP versus iCCA incidence trends, with overall greater absolute change in iCCA incidence, provide evidence for a true increase in iCCA incidence that may not be wholly attributable to CUP reclassification.
Urine eosinophil‐derived neurotoxin: A potential marker of activity in select eosinophilic disorders
Makiya, Michelle , Khoury, Paneez , Kuang, Fei Li , Mata, Alexis Dominique , Mahmood, Sana , Bowman, Abbie, Kovacs, Nicholas A. , Holland, Nicole, Dyer, Anne‐Marie , Akuthota, Praveen , Gleich, Gerald J. , Langford, Carol A. , Weller, Peter F. , Makiya, Michelle A , Wetzler, Lauren , Dyer, Anne-Marie , Bochner, Bruce S , Chinchilli, Vernon M , Gleich, Gerald J , Merkel, Peter A , Specks, Ulrich , Weller, Peter F , Wechsler, Michael E , Prussin, Calman , Klion, Amy D , Mahmood, Sana, Espinoza, David, Kovacs, Nicholas, Brown, Thomas , Ware, JeanAnne M. , Bochner, Bruce S. , Merkel, Peter A. , Specks, Ulrich , Fay, Michael P. , Klion, Amy D.

Mayo Clinic

Allergy | August 16, 2022 | Volume: 78 | Issue: 1 | Pages: 258-269

10.1111/all.15481 | PMID 35971862 Get It

AbstractBackgroundBiomarkers of eosinophilic disease activity, especially in the context of novel therapies that reduce blood eosinophil counts, are an unmet need. Absolute eosinophil count (AEC) does not accurately reflect tissue eosinophilia or eosinophil activation. Therefore, the aims of this study were to compare the reliability of plasma and urine eosinophil major basic protein 1, eosinophil cationic protein, eosinophil‐derived neurotoxin (EDN), and eosinophil peroxidase measurement and to evaluate the usefulness of eosinophil granule protein (EGP) measurement for the assessment of disease activity in patients with eosinophil‐associated diseases treated with mepolizumab, benralizumab, or dexpramipexole.MethodsEosinophil granule protein concentrations were measured in serum, plasma, and urine from healthy volunteers and patients with hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), and eosinophilic asthma using a multiplex assay.ResultsUrine EGP concentrations remained stable, whereas serum and plasma EGP concentrations increased significantly with delayed processing. Plasma (p) EDN, but not urine (u) EDN, concentration correlated with AEC and negatively correlated with prednisone dose. Both pEDN and uEDN decreased significantly following treatment of HES patients with benralizumab and EGPA patients with mepolizumab. uEDN appeared to increase with clinical relapse in both patient groups.ConclusionsMeasurement of EGP in urine is noninvasive and unaffected by cellular lysis. Although plasma and urine EDN concentrations showed a similar pattern following benralizumab and mepolizumab treatment, the lack of correlation between AEC or prednisone dose and uEDN concentrations suggests that measurement of uEDN may provide a potential biomarker of disease activity in patients with HES and EGPA.
Commentary: Transcallosal Transchoroidal Approach to the Third Ventricle for Resection of a Thalamic Cavernoma—Anatomical Landmarks Review: 3-Dimensional Operative Video
Bauman, Megan M. J. , Patra, Devi Prasad, Patra, Devi P. , Bauman, Megan , Bendok, Bernard R.

Mayo Clinic

Operative Neurosurgery | August 16, 2022 | Volume: 23 | Issue: 3 | Pages: e211-e213

10.1227/ons.0000000000000353 | PMID 35972121 Get It

Commentary: Cavernous Hemangioma of the Cavernous Sinus—Same Pathology, Different Disease: 2-Dimensional Operative Video
Patra, Devi Prasad, Turcotte, Evelyn L. , Bendok, Bernard R. , Patra, Devi P. , Bendok, Bernard R , Singh, Rohin , Rath, Tanya J.

Mayo Clinic

Operative Neurosurgery | August 16, 2022 | Volume: 23 | Issue: 3 | Pages: e199-e200

10.1227/ons.0000000000000332 | PMID 35972115 Get It